Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.65 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.65 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.65 |
| ▸ | SRC | P12931 | 3/20 | 0.65 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | PTPRC | P08575 | 3/20 | 0.49 |
| ▸ | S100A4 | P26447 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145179 | 0.95 | FGFR1 (0.65) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL144476 | 0.81 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL3578768 | 0.81 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL143675 | 0.80 | FGFR1 (1.00) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL146452 | 0.80 | FGFR1 (0.72) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL27218306 | 0.79 | FGFR1 (0.74) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL4656306 | 0.78 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3SRC | |
| SCHEMBL5935194 | 0.77 | PTGDR2 (0.54) | PTGS2PTGDR2POLBRAB9ASLC6A4 | |
| SCHEMBL30338973 | 0.77 | PTGDR2 (0.54) | PTGS2PTGDR2POLBRAB9ASLC6A4 | |
| SCHEMBL15229768 | 0.77 | MYC (0.55) | PPARGPTGS2PTGDR2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | FGFR1 5/4885FGFR2 6/4885FGFR4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.